Biotechnology | Disease | FDA | Medicine | Therapeutics
Dupixent approved in the U.S. as the only targeted medicine to treat patients with bullous pemphigoid
On Jun. 20, 2025, the US Food and Drug Administration (FDA) announced it has approved Dupixent (dupilumab) for…